Hospital Universitario Infanta Leonor

At Hospital Universitario Infanta Leonor in Madrid, a major share of research focuses on hemic and lymphatic diseases and neoplasms, especially multiple myeloma, leukemias, and lymphomas. These studies are mainly designed to test new treatment approaches, improve disease control, and deepen understanding of response and resistance in blood cancers.

• Multiple myeloma, including newly diagnosed, relapsed, and transplant-eligible patients
• Chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma
• Acute myeloid leukemia and related high-risk blood disorders

These trials commonly compare emerging therapies with standard care to improve survival, response rates, and long-term disease control in hematologic cancer care.

This site also has a strong program in immune system diseases and autoimmune disorders, with research spanning systemic lupus erythematosus, Sjögren’s disease, psoriatic arthritis, and idiopathic inflammatory myopathies. The goal is to evaluate therapies that may reduce inflammation, improve symptoms, and better control chronic immune activation.

• Systemic lupus erythematosus and related autoimmune activity
• Sjögren’s syndrome and primary Sjögren’s disease
• Psoriatic arthritis and inflammatory myopathies

Research in this area reflects a broader effort to find safer and more effective options for people living with long-term inflammatory conditions.

Clinical trials at the site include a broad set of skin and connective tissue diseases and allergic conditions, such as atopic dermatitis, plaque psoriasis, alopecia areata, vitiligo, and allergic rhinoconjunctivitis. Several studies are also exploring eosinophilic inflammation in asthma and related disorders, with the purpose of improving symptom control and long-term disease management.

• Atopic dermatitis and other chronic inflammatory skin diseases
• Severe asthma, including eosinophilic and uncontrolled forms
• Allergic rhinoconjunctivitis, alopecia areata, and nonsegmental vitiligo

These studies focus on reducing disease burden, improving quality of life, and identifying better-targeted immune therapies.

Another important area is respiratory tract diseases and infectious diseases, with trials in asthma, chronic obstructive pulmonary disease, tuberculosis, COVID-19, and pulmonary fibrosis. The research aims to improve breathing outcomes, reduce exacerbations, and evaluate new strategies for difficult-to-treat lung conditions.

• Asthma, including severe and eosinophilic subtypes
• Chronic obstructive pulmonary disease and related cardiopulmonary outcomes
• Tuberculosis, COVID-19, and progressive fibrosing interstitial lung disease

The respiratory portfolio at Hospital Universitario Infanta Leonor highlights efforts to refine treatment effectiveness and support patients with chronic or high-risk lung disease.

Trials in digestive system diseases, nutritional and metabolic diseases, and renal disorders address conditions such as Crohn’s disease, ulcerative colitis, type 2 diabetes, hyperuricemia associated with gout, and immunoglobulin A nephropathy. These studies are designed to test new therapies, improve disease control, and protect organ function over time.

• Crohn’s disease and ulcerative colitis
• Type 2 diabetes and elevated lipoprotein(a)
• IgA nephropathy and acute gout flares

Research in these fields reflects a practical focus on chronic disease management and prevention of long-term complications.

The site participates in trials across cardiovascular diseases and related internal medicine areas, including acute heart failure, atherosclerotic cardiovascular disease, venous thromboembolism, and hypertension. The main purpose is to evaluate whether newer treatments can lower risk, improve outcomes, and better support patients with complex chronic disease.

• Acute heart failure and broader cardiovascular risk
• Atherosclerotic cardiovascular disease and elevated lipoprotein(a)
• Venous thromboembolism and hypertension

These studies add to a broad research profile that includes both prevention and treatment-focused cardiovascular care.

Beyond blood cancers, the research portfolio includes solid tumor studies in breast neoplasms, non-small cell lung cancer, colorectal cancer, and head and neck cancer. These trials are generally aimed at improving treatment effectiveness, extending disease control, and evaluating combination strategies in advanced or high-risk cancer settings.

• Breast cancer, including early, hormone receptor-positive, and triple-negative disease
• Non-small cell lung cancer and oligometastatic disease
• Colorectal cancer and head and neck squamous cell carcinoma

This oncology research adds breadth to the site’s clinical trial activity and supports testing of innovative cancer therapies across multiple tumor types.

Several studies address virus diseases and chronic infectious conditions such as hepatitis B and HIV, alongside research in bacterial infections and immune-related complications. The focus is on improving long-term viral suppression, reducing disease activity, and exploring approaches that may support durable control or functional cure.

• Chronic hepatitis B and treatment-related viral control
• HIV infections and maintenance of virologic suppression
• Bacilliferous pulmonary tuberculosis and other serious infections

These trials reflect a commitment to advancing care for chronic infections that require sustained treatment and monitoring.